Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function

Kidney International

Volumn 85, Issue 2, 2014, Pages 344-351

  Hughes, Kim ^a   Flynn, Tanya ^a   De Zoysa, Janak ^b   Dalbeth, Nicola ^c   Merriman, Tony R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

creatinine; Mendelian randomization; renal; renal function decline; urate; uric acid transporter

Indexed keywords

CREATININE; URATE; URATE TRANSPORTER; XANTHINE OXIDASE INHIBITOR;

ARTICLE; CREATININE BLOOD LEVEL; DRUG MECHANISM; FEMALE; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC RISK; GENETIC VARIABILITY; GLOMERULUS FILTRATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; PRIORITY JOURNAL; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

BIOLOGICAL MARKERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CREATININE; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MODELS, GENETIC; MODELS, STATISTICAL; ORGANIC ANION TRANSPORTERS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; RECOVERY OF FUNCTION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; UP-REGULATION; URIC ACID; XANTHINE OXIDASE;

EID: 84895903190     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.353     Document Type: Article

References (42)

1. Bellomo G, Venanzi S, Verdura C et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010; 56: 264-272
2. Weiner DE, Tighiouart H, Elsayed EF et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19: 1204-1211
3. Wang H, Wei Y, Kong X et al. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: A meta-Analysis. J Renal Nutr 2012; 23: 389-396
4. Kang DH, Kanellis J, Hugo C et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-816
5. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-F997
6. Sanchez-Lozada LG, Tapia E, Santamaria J et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247
7. Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: Confounders, culprits, and circles. Am J Kidney Dis 2010; 56: 247-250
8. Smith GD, Lawlor D, Harbord R et al. Clustered environments and randomized genes: A fundamental distinction between conventional and genetic epidemiology. PLoS Med 2007; 4: E352
9. Kang DH, Chen W. Uric acid and chronic kidney disease: New understanding of an old problem. Semin Nephrol 2011; 31: 447-452
10. George J, Carr E, Davies J et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-2516
11. Goicoechea M, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393
12. Kanbay M, Huddam B, Azak A et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011; 6: 1887-1894
13. Kanbay M, Ozkara A, Selcoki Y et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227-1233
14. Siu YP, Leung K, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59
15. Yang Q, Köttgen A, Dehghan A et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010; 3: 523-530
16. Hollis-Moffatt JE, Phipps-Green AJ, Chapman B et al. The renal urate transporter SLC17A1 locus: Confirmation of association with gout. Arthritis Res Ther 2012; 14: R92
17. Hollis-Moffatt JE, Xu X, Dalbeth N et al. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific Island, and Caucasian case-control sample sets. Arthritis Rheum 2009; 60: 3485-3492
18. Phipps-Green AJ, Hollis-Moffatt JE, Dalbeth N et al. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets. Hum Mol Genet 2010; 19: 4813-4819
19. Kottgen A, Albrecht E, Teumer A et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013; 45: 145-154
20. Dalbeth N, House ME, Gamble GD et al. Population specific influence of SLC2A9 genotype on the acute hyperuricemic response to a fructose load. Ann Rheum Dis 2013 (e-pub ahead of print
21. Oikonen M, Wendelin-Saarenhovi M, Lyytikäinen LP et al. Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. Atherosclerosis 2012; 223: 497-503
22. Lyngdoh T, Vuistiner P, Marques-Vidal P et al. Serum uric acid and adiposity: Deciphering causality using a bidirectional Mendelian randomization approach. PLoS One 2012; 7: E39321
23. Parsa A, Brown E, Weir MR et al. Genotype-based changes in serum uric acid affect blood pressure. Kidney Int 2012; 81: 502-507
24. Pfister R, Barnes D, Luben R et al. No evidence for a causal link between uric acid and type 2 diabetes: A Mendelian randomisation approach. Diabetologia 2011; 54: 2561-2569
25. McKeigue PM, Campbell H, Wild S et al. Bayesian methods for instrumental variable analysis with genetic instruments ('Mendelian randomization'): Example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol 2010; 39: 907-918
26. Lawlor DA, Harbord RM, Sterne JA et al. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27: 1133-1163
27. Sheehan NA, Meng S, Didelez V. Mendelian randomisation: A tool for assessing causality in observational epidemiology. Methods Mol Biol 2011; 713: 153-166
28. Didelez V SN. Mendelian randomization as an instrumental variable approach to causal inference. Stat Method Med Res 2007; 16: 309-330
29. Burgess S, Thompson SG. Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011; 40: 755-764
30. Timpson NJ, Lawlor DA, Harbord RM et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 2005; 366: 1954-1959
31. Iwanaga T, Kobayashi D, Hirayama M et al. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent benzbromarone. Drug Metab Dispos 2005; 33: 1791-1795
32. Fujimori S, Ooyama K, Ooyama H et al. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1035-1038
33. Malaguarnera M, Vacante M, Russo C et al. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Exp Opin Pharmacother 2009; 10: 737-742
34. Glantzounis GK, Tsimoyiannis EC, Kappas AM et al. Uric acid and oxidative stress. Curr Pharmaceut Des 2005; 11: 4145-4151
35. Anzai N, Endou H. Urate transporters: An evolving field. Semin Nephrol 2011; 31: 400-409
36. Gibson T, Waterworth R, Hatfield P et al. Hyperuricemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol 1984; 23: 276-282
37. Simmonds HA, McBride MB, Hatfield PJ et al. Polynesian women are also at risk for hyperuricemia and gout because of a genetic defect in renal urate handling. Br J Rheumatol 1994; 33: 932-937
38. Crowley LV. Determination of uric acid: An automated analysis based on a carbonate method. Clin Chem 1964; 10: 838-844
39. Hausman JA. Specification tests in econometrics. Econometrica 1978; 46: 1251-1271
40. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006; 2: E190
41. Cao F, Wang X, Lu M et al. Glucokinase Regulatory Protein (GCKR) Gene rs4425043 Polymorphism is Associated with Overweight and Obesity in Chinese Women. Lipids 2011; 46: 357-363
42. Pierce BL, Ahsan H, VanderWeele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 2011; 40: 740-752